A practical nomogram and risk stratification system for predicting survival outcomes in neuroblastoma patients: a SEER population-based study

被引:1
作者
Zhuo, Xiaoyu [1 ]
Xia, Liangfeng [2 ]
Tang, Wenjing [1 ]
He, Wenqi [2 ]
机构
[1] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Pediat Hematol & Oncol, Chengdu 611731, Peoples R China
[2] Univ Elect Sci & Technol China, Chengdu Womens & Childrens Cent Hosp, Sch Med, Dept Pediat Surg, Chengdu 611731, Peoples R China
关键词
Neuroblastoma; Nomogram; Prognosis; Risk stratification system; CHEMOTHERAPY; SURGERY;
D O I
10.1007/s00432-023-05110-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeuroblastoma (NB) is a childhood malignancy with marked heterogeneity, resulting in highly variable outcomes among patients. This study aims to establish a novel nomogram and risk stratification system to predict the overall survival (OS) for patients with NB.MethodsWe analyzed neuroblastoma patients from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The nomogram was constructed using independent risk factors for OS, identified through univariate and multivariate Cox regression analyses. The accuracy of this nomogram was evaluated with the concordance index, receiver operating characteristic curve, calibration curve, and decision curve analysis. In addition, we developed a risk stratification system based on the total score of each patient in the nomogram.ResultsA total of 2185 patients were randomly assigned to the training group and the testing group. Six risk factors, including age, chemotherapy, brain metastases, primary site, tumor stage, and tumor size, were identified in the training group. Using these factors, a nomogram was constructed to predict 1-, 3-, and 5-year OS of NB patients. This model exhibited superior accuracy in the training and testing groups, exceeding traditional tumor stage prediction. Subgroup analysis suggested worse prognosis for retroperitoneal origin in the intermediate-risk group and adrenal gland origin in the high-risk group compared to other sites. Additionally, the prognosis for high-risk patients significantly improved after surgery. We also developed a web application to make the nomogram more user-friendly in clinical practices.ConclusionThis nomogram demonstrates excellent accuracy and reliability, offering more precise personalized prognostic predictions to clinical patients.
引用
收藏
页码:12285 / 12296
页数:12
相关论文
共 23 条
  • [1] Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma.
    Baker, David L.
    Schmidt, Mary L.
    Cohn, Susan L.
    Maris, John M.
    London, Wendy B.
    Buxton, Allen
    Stram, Daniel
    Castleberry, Robert P.
    Shimada, Hiroyuki
    Sandler, Anthony
    Shamberger, Robert C.
    Look, A. Thomas
    Reynolds, C. Patrick
    Seeger, Robert C.
    Matthay, Katherine K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14) : 1313 - 1323
  • [2] Brodeur G, 2002, PRINCIPLES PRACTICE
  • [3] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477
  • [4] Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States
    Coughlan, Diarmuid
    Gianferante, Matthew
    Lynch, Charles F.
    Stevens, Jennifer L.
    Harlan, Linda C.
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (05) : 320 - 330
  • [5] Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas
    El Sharouni, Mary-Ann
    Ahmed, Tasnia
    Varey, Alexander H. R.
    Elias, Sjoerd G.
    Witkamp, Arjen J.
    Sigurdsson, Vigfus
    Suijkerbuijk, Karijn P. M.
    van Diest, Paul J.
    Scolyer, Richard A.
    van Gils, Carla H.
    Thompson, John F.
    Blokx, Willeke A. M.
    Lo, Serigne N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1243 - +
  • [6] Clinical characteristics, treatment and prognosis of paediatric patients with metastatic neuroblastoma to the brain
    Hu, Huimin
    Zhang, Weiling
    Huang, Dongsheng
    Wang, Yizhuo
    Zhang, Yi
    Yi, You
    Liu, Aiping
    Li, Jing
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2019, 184
  • [7] Neuroblastoma Paradigm for Precision Medicine
    Irwin, Meredith S.
    Park, Julie R.
    [J]. PEDIATRIC CLINICS OF NORTH AMERICA, 2015, 62 (01) : 225 - +
  • [8] Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non-Small-Cell Lung Cancer
    Liang, Wenhua
    Zhang, Li
    Jiang, Gening
    Wang, Qun
    Liu, Lunxu
    Liu, Deruo
    Wang, Zheng
    Zhu, Zhihua
    Deng, Qiuhua
    Xiong, Xinguo
    Shao, Wenlong
    Shi, Xiaoshun
    He, Jianxing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 861 - +
  • [9] SUMOylation is essential for Sirt2 tumor-suppressor function in neuroblastoma
    Lu, Wenmei
    Wang, Qian
    Xu, Ci
    Yuan, Haihua
    Fan, Qiang
    Chen, Biying
    Cai, Renjie
    Wu, Danhong
    Xu, Ming
    [J]. NEOPLASIA, 2021, 23 (01): : 129 - 139
  • [10] Medical Progress: Recent Advances in Neuroblastoma.
    Maris, John M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (23) : 2202 - 2211